MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 885 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
pan-KRAS-IN-2
CAS:<p>Pan-KRAS-IN-2 (compound 6) is a broad-spectrum KRAS inhibitor exhibiting potent activity with IC50 values of ≤10 nM against KRAS wild type and its mutants (G12D</p>Formula:C34H34F2N4O3Purity:98%Color and Shape:SolidMolecular weight:584.66SB-682330A
CAS:<p>SB-682330A is a Raf kinase inhibitor.</p>Formula:C28H27N3O3Color and Shape:SolidMolecular weight:453.53TC13172
CAS:<p>TC13172 is a potent, covalent MLKL inhibitor, selective over RIPK1/RIPK3. It blocks TSZ-induced necroptosis (EC50=2nM) and MLKL oligomerization at 100nM.</p>Formula:C17H16N4O5SPurity:98%Color and Shape:SolidMolecular weight:388.4KRAS degrader-1
CAS:<p>KRAS degrader-1 (compound 1) is a potent agent that selectively targets KRAS proteins for destruction via the autophagy-lysosomal degradation pathway [1].</p>Formula:C55H57Br2ClFIN8O7Color and Shape:SolidMolecular weight:1283.25Cobimetinib racemate
CAS:<p>Cobimetinib racemate (Cobimetinib (racemate)) (GDC-0973 racemate) is a selective inhibitor of MEK.Cobimetinib racemate is also known as a mitogen-activated</p>Formula:C21H21F3IN3O2Purity:98.00% - 99.71%Color and Shape:SolidMolecular weight:531.31Kras binder 12
CAS:<p>Kras binder 12 can be used in studies about Ras.</p>Formula:C29H47N9O6Color and Shape:SoildMolecular weight:617.74ARQ-736
CAS:<p>ARQ 736 effectively targets and inhibits BRAF, crucial in MAPK pathway, beneficial for treating melanomas and certain colon cancers.</p>Formula:C25H25N8Na2O8PSColor and Shape:SolidMolecular weight:674.54Ilaprazole sodium hydrate
CAS:<p>Ilaprazole sodium hydrate (IY-81149 sodium hydrate) is a proton pump inhibitor that blocks the transport of HSV particles.</p>Formula:C19H21N4NaO4SPurity:99.2%Color and Shape:SolidMolecular weight:424.45KRAS G12C inhibitor 17
CAS:<p>KRAS G12C inhibitor 17 is a potent KRAS G12C inhibitor.</p>Formula:C24H20ClF2N3O3Purity:98%Color and Shape:SolidMolecular weight:471.88ARS-1323-alkyne
CAS:<p>ARS-1323-alkyne is a switch-II pocket (S-IIP) inhibitor and a conformational specific chemical reporter of KRASG12C nucleotide state in living cells.</p>Formula:C28H27ClF2N6O3Purity:98.00% - 99%Color and Shape:SolidMolecular weight:569ERK1/2 inhibitor 5
CAS:<p>ERK1/2 inhibitor 5: potent against ERK1/2, may combat cancer and inflammation.</p>Formula:C28H32ClFN6O5Color and Shape:SolidMolecular weight:587.04ARS-1323
CAS:<p>ARS-1323 is the racemate of ARS-1620 and a mutant K-ras G12C inhibitor.</p>Formula:C21H17ClF2N4O2Purity:99.53%Color and Shape:SolidMolecular weight:430.84KRAS G12C inhibitor 32
CAS:<p>KRAS G12C Inhibitor 32, an eight-membered heterocyclic compound with nitrogen, acts as a potent inhibitor of KRAS G12C [1].</p>Formula:C29H30Cl3FN6O3Purity:98%Color and Shape:SolidMolecular weight:635.94TH-Z827
CAS:<p>TH-Z827 is a mutant-selective inhibitor targeting KRAS(G12D) with an IC50 of 2.4 μM, demonstrating specificity by not binding to KRAS(WT) or KRAS(G12C).</p>Formula:C30H38N6OPurity:98%Color and Shape:SolidMolecular weight:498.66HPK1-IN-9
CAS:<p>HPK1-IN-9: Potent MAP4K family kinase inhibitor targeting hematopoietic progenitor cells; potential in HPK1 diseases. (Patent WO2021213317A1)</p>Formula:C30H33N7O2Color and Shape:SolidMolecular weight:523.63CHI-000-667
CAS:<p>CHI-000-667 can be used in studies about Ras.</p>Formula:C21H16ClNO4SColor and Shape:SolidMolecular weight:413.87KRAS G12C inhibitor 28
CAS:<p>KRAS G12C Inhibitor 28 is a compound that effectively inhibits the KRAS G12C mutation, exhibiting potent antitumor effects with an inhibitory concentration (</p>Formula:C33H36F2N5O4PColor and Shape:SolidMolecular weight:635.64K-Ras G12C-IN-2
CAS:<p>K-Ras G12C-IN-2 is a covalent kras g12c inhibitor.</p>Formula:C21H27ClN4O3Purity:98%Color and Shape:SolidMolecular weight:418.92SHP2-IN-22
CAS:<p>SHP2-IN-22, a potent SHP2 allosteric inhibitor, exhibits an IC50 value of 17.7 nM and effectively suppresses proliferation, migration, and invasion in MIA PaCa-</p>Formula:C23H22Cl2N8OColor and Shape:SolidMolecular weight:497.38KRAS G12C inhibitor 40
CAS:<p>KRAS G12C inhibitor 40 targets KRAS G12C in cancer research (WO2021129824A1, compound 70).</p>Formula:C34H36ClFN10O2Color and Shape:SolidMolecular weight:671.17HPK1 antagonist-1
CAS:<p>HPK1 antagonist-1 (I-792) is an inhibitor targeting HPK1, with potential applications in cancer and immune disease research [1].</p>Formula:C28H29FN6O2Color and Shape:SolidMolecular weight:500.57Exarafenib
CAS:<p>Exarafenib (RAF/KIN_2787) is an oral pan-RAF inhibitor with antitumor properties, targeting MAPK signaling in cancer research.</p>Formula:C26H34F3N5O3Purity:98.36% - 99.84%Color and Shape:SolidMolecular weight:521.58Kras4B G12D-IN-1
CAS:<p>Kras4B G12D-IN-1 is an inhibitor of Kras4B G12D with anticancer activity.Kras4B G12D-IN-1 inhibits Kras protein expression.</p>Formula:C16H21ClN2O4SPurity:99.75%Color and Shape:SolidMolecular weight:372.87HG6-64-1
CAS:<p>HG6-64-1 (HMSL 10017-101-1, compound 9 (XI-1)) is a potent and selective B-Raf inhibitor with an IC50 = 0.09 μM in B-raf V600E-transformed Ba/F3 cells.</p>Formula:C32H34F3N5O2Purity:99.89%Color and Shape:SolidMolecular weight:577.64ZYF0033
CAS:<p>ZYF0033(HPK1-IN-22) is an orally effective inhibitor of HPK1 that inhibits the phosphorylation of MBP proteins and decreases the phosphorylation of SLP76.</p>Formula:C26H30N4O2SPurity:99.70%Color and Shape:SolidMolecular weight:462.61JWG-071
CAS:<p>JWG-071: First ERK5 kinase probe, BET inhibitor, 1 μM BRD4 IC, boosts ERK5 function and BRD4 selectivity.</p>Formula:C34H44N8O3Purity:98.33%Color and Shape:SolidMolecular weight:612.77BI-2493
CAS:<p>BI-2493 is a highly selective pan-KRAS inhibitor and structural analog of BI-2865.BI-2493 exhibits antitumor activity and inhibits tumor cell growth.Cost-effective and quality-assured.</p>Formula:C24H27N7OSPurity:97.74% - 99.88%Color and Shape:SoildMolecular weight:461.58Pan-RAS-IN-1
CAS:<p>Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors.</p>Formula:C36H41Cl2F3N6O2Purity:99.77%Color and Shape:SolidMolecular weight:717.65MK-8353
CAS:<p>MK-8353 (SCH900353) is a potent, selective and orally available inhibitor of ERK1/2 (IC50s of 23.0 nM and 8.8 nM, respectively)</p>Formula:C37H41N9O3SPurity:96.15% - 97.19%Color and Shape:SolidMolecular weight:691.84KRAS G12C inhibitor 50
CAS:<p>KRAS G12C inhibitor 50 is a KRAS G12C inhibitor (IC50: 46.7 nM).</p>Formula:C31H34N8O2Color and Shape:SolidMolecular weight:550.65MK2-IN-4
CAS:<p>MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor (IC50: 45 nM). MK2-IN-4 can be used in cancer, inflammation and immunology studies.</p>Formula:C25H24N4O2Color and Shape:SolidMolecular weight:412.48KRAS inhibitor-36
CAS:<p>KRAS inhibitor-36 (compound Abd2) directly inhibits KRAS Q61H.</p>Formula:C14H13NO4Color and Shape:SolidMolecular weight:259.26KRASG12C IN-12
CAS:<p>KRASG12C IN-12 (compound-1) acts as an inhibitor of KRASG12C. It forms a ternary complex with intracellular CYPA and the activated mutant of KRASG12C.</p>Formula:C29H39N5O6S2Color and Shape:SolidMolecular weight:617.78KRAS G12D inhibitor 19
CAS:<p>KRAS G12D inhibitor 19 (Compound 7) is used in cancer research [1]. As a specific inhibitor of KRAS G12D, it targets and potentially suppresses this mutation, which is frequently associated with various cancers.</p>Formula:C35H34F2N6O3Color and Shape:SolidMolecular weight:624.68AZD4625
<p>AZD4625 (Compound 21) is a selective, potent, orally active, covalent and mutagenic mutant GTPaseKRASG12C inhibitor.</p>Formula:C24H21ClF2N4O3Color and Shape:SolidMolecular weight:486.9KRAS ligand 3
CAS:<p>KRAS ligand 3 (compound 1), a BTX-6654 target-binding ligand, exhibits synergistic tumor growth inhibition through its capacity to bind a KRAS inhibitor [1].</p>Formula:C24H28F3N5Color and Shape:SolidMolecular weight:443.51PAT-IN-1
CAS:<p>PAT-IN-1, a protein acyl transferases (PAT) inhibitor, competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13) [1].</p>Formula:C45H68N4OColor and Shape:SolidMolecular weight:681.05KRAS G12C inhibitor 46
CAS:<p>KRAS G12C inhibitor 46 is a potent inhibitor of KRAS G12C.</p>Formula:C32H33F2N7O2Color and Shape:SolidMolecular weight:585.65Calderasib
CAS:<p>Calderasib (MK-1084) is a selective KRAS G12C inhibitor (IC50 1.2 nM) with anticancer activity, usable as monotherapy or combined with PD-1 inhibitors</p>Formula:C32H31ClF2N6O4Purity:98.69%Color and Shape:SolidMolecular weight:637.08BBO-8520
CAS:<p>BBO-8520 is a dual KRASG12C inhibitor that blocks ON and OFF states, disables effector binding, suppresses signaling, and induces tumor regression.</p>Formula:C35H33F6N7O2SPurity:97.879%Color and Shape:SolidMolecular weight:729.74KRAS inhibitor-35
CAS:<p>KRAS inhibitor-35 (compound 72) is a KRAS inhibitor with an IC50 of 2 nM, utilized in tumor research.</p>Formula:C38H32F4N6O3SColor and Shape:SolidMolecular weight:728.76COTI-219
CAS:<p>COTI-219 is an oral inhibitor of KRAS with antitumor properties [1].</p>Formula:C17H18N6SColor and Shape:SolidMolecular weight:338.43pan-KRAS-IN-6
CAS:<p>Pan-KRAS-IN-6 (compound 12) is a potent pan-KRAS inhibitor, with IC50 values of 9.79 nM for Kras G12D and 6.03 nM for Kras G12V.</p>Formula:C29H30ClF3N6O3SColor and Shape:SolidMolecular weight:635.10KRASG12D-IN-3-d3
CAS:<p>KRASG12D-IN-3-d3 is the deuterium labeled KRASG12D-IN-3. KRASG12D-IN-3 (compound Z1084) is a KRASG12D inhibitor with oral bioactivity that can effectively inhibit the growth of tumor cells AGS and AsPC-1, with IC50 values of 0.38 nM and 1.23 nM, respectively.</p>Formula:C31H27D3ClF6N7O2Color and Shape:SoildMolecular weight:685.08KRAS inhibitor-21
CAS:<p>KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor (IC50<0.01 μM) that can be used in cancer research.</p>Formula:C33H41N5O3Color and Shape:SolidMolecular weight:555.71Everafenib
<p>Everafenib: potent BRAF inhibitor, crosses blood-brain barrier, hinders MAPK, effective on V600EBRAF cells, outperforms other drugs in trials.</p>Formula:C20H23ClFN5O2S2Color and Shape:SolidMolecular weight:484.01Famlasertib
CAS:<p>Famlasertib is a potent inhibitor of the mitogen-activated protein kinase kinase kinase kinase (MAP4K) family, capable of penetrating the brain. It exhibits an IC50 value of 0.3 nM for HGK (MAP4K4) and 23.7 nM for MLK3.</p>Formula:C26H27ClN4OColor and Shape:SolidMolecular weight:446.972TH-Z816
CAS:<p>TH-Z816 acts as a reversible inhibitor targeting the KRAS(G12D) mutation, exhibiting an IC50 of 14 µM. This compound is utilized in cancer research [1].</p>Formula:C29H38N6OColor and Shape:SolidMolecular weight:486.65G12Si-1
<p>G12Si-1 selectively binds and inhibits K-Ras(G12S) to block oncogenic signaling and nucleotide exchange.</p>Formula:C29H32ClN5O3Color and Shape:SolidMolecular weight:534.05HPK1-IN-41
CAS:<p>HPK1-IN-41 (compound Z389) functions as an HPK1 inhibitor, exhibiting an IC50 value of 0.21 nM [1].</p>Formula:C28H33N5O2Color and Shape:SolidMolecular weight:471.59(+)-Perillyl alcohol
CAS:<p>(+)-Perillyl alcohol (0.25-1 mM) inhibits cell growth in SW480 cells. At a concentration of 1 mM and a duration of 24 hours, (+)-Perillyl alcohol increases the number of cells in the G0/G1 phase and reduces the number in the S phase in SW480 cells.</p>Formula:C10H16OColor and Shape:SolidMolecular weight:152.23MAP855
CAS:<p>MAP855: potent, selective, oral MEK1/2 inhibitor; IC50=3 nM, pERKEC50=5 nM; effective on wild-type/mutant MEK1/2.</p>Formula:C28H23ClF2N6O3Color and Shape:SolidMolecular weight:564.97MBA-m1
CAS:<p>MBA-m1 is an MLKL inhibitor that suppresses necroptosis in Mlkl−/−NIH-3T3 cells. Additionally, MBA-m1 alleviates disease conditions in mouse models of dermatitis and abdominal aortic aneurysm induced by MLKL.</p>Formula:C27H21ClN2O2Color and Shape:SolidMolecular weight:440.92ZCL279
CAS:<p>ZCL279 is a small molecule modulator (SMM) that inhibits the interaction between CDC42 and intersectin (ITSN). At lower concentrations (<10 μM), ZCL279 activates Cdc42, a cytoplasmic small GTPase in the Ras superfamily, while at higher concentrations (<10 μM) it significantly inhibits it.</p>Formula:C24H18N2O7S2Color and Shape:SolidMolecular weight:510.539Anti-osteoporosis agent-11
CAS:<p>Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. It exhibits its most prominent effect by inhibiting osteoclast differentiation, with an IC50 value of 0.36 μM. Additionally, Anti-osteoporosis agent-11 suppresses osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking the RANKL-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways.</p>Formula:C23H17NO2Se2Color and Shape:SolidMolecular weight:497.31KRAS G12D inhibitor 28
CAS:<p>KRAS G12D inhibitor 28 (Compound 1) is an inhibitor of KRAS G12D and can be utilized in cancer research.</p>Formula:C35H32Cl2FN5OColor and Shape:SolidMolecular weight:628.57MLKL-IN-1
<p>MLKL-IN-1 is a covalent inhibitor of MLKL with a Kd value of 50 μM.</p>Formula:C19H20N2O3Color and Shape:SolidMolecular weight:324.37INCB159020
CAS:<p>INCB159020 is an orally active inhibitor of KRAS G12D, exhibiting a KRAS G12D SPR value of 2.2 nM. It demonstrates anti-tumor activity.</p>Formula:C37H35ClFN7O2Color and Shape:SolidMolecular weight:664.171GDC-6036-NH
CAS:<p>GDC-6036-NH is a precursor of compound 17a /b, which is a RAS inhibitor that can be used in cancer research.</p>Formula:C26H30ClF4N7OPurity:99.84%Color and Shape:SolidMolecular weight:568.01KRAS inhibitor-13
CAS:<p>KRAS inhibitor-13 blocks KRAS G12C (IC50: 0.883 μM) and p-ERK in some cancer cells; promising for pancreatic, colorectal, lung cancer research.</p>Formula:C25H19ClFN3O2SColor and Shape:SolidMolecular weight:479.95HPK1-IN-42
CAS:<p>HPK1-IN-42 (compound 185) is an inhibitor of HPK1, displaying potent activity with an IC50 of 0.24 nM [1].</p>Formula:C26H30N6OSColor and Shape:SolidMolecular weight:474.62AMG-548 hydrochloride
<p>AMG-548 hydrochloride: orally active, p38α inhibitor (Ki=0.5 nM), 1000x less for p38γ/δ, also blocks TNFα (IC50=3 nM) & inhibits casein kinase 1 δ/ε.</p>Formula:C29H28ClN5OColor and Shape:SolidMolecular weight:498.02SHR902275
CAS:<p>SHR902275: potent RAF inhibitor, hits RAS mutations, oral use. cRAF IC50=1.6 nM, bRAFwt IC50=10 nM, bRAFV600E IC50=5.7 nM, hinders cell growth.</p>Formula:C26H23F3N4O4Color and Shape:SolidMolecular weight:512.48JD123
CAS:<p>JD123 inhibits the activity of JNK1 and the expression of cJun (1-135). It is an ATP-competitive inhibitor specific to p38-γ MAPK and has no effect on ERK1, ERK2, p38-α, p38-β, and p38-δ.</p>Formula:C12H11N5S2Color and Shape:SolidMolecular weight:289.379ERK1/2 inhibitor 6
CAS:<p>ERK1/2 inhibitor 6 - potent cancer/inflammation treatment from WO2021063335A1.</p>Formula:C27H29ClFN7O5Color and Shape:SolidMolecular weight:586.01RSK4-IN-1
CAS:<p>RSK4-IN-1 is a compound exhibiting potent inhibition of RSK4, demonstrated by an IC50 value of 9.5 nM.</p>Formula:C19H20F2N4O3Color and Shape:SolidMolecular weight:390.38HPK1-IN-3
<p>HPK1-IN-3: Selective HPK1 inhibitor, ATP-competitive, IC50=0.25nM; boosts IL-2 in PBMCs, EC50=108nM.</p>Formula:C23H22F4N6O2Color and Shape:SolidMolecular weight:490.45SOS1-IN-9
<p>SOS1-IN-9 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 116.5 nM).</p>Formula:C22H28F3N5OColor and Shape:SolidMolecular weight:435.49KRAS inhibitor-41
CAS:<p>KRAS inhibitor-41 is a KRAS inhibitor with an IC50 value of less than 0.01 μM for both KRAS G12D and KRAS G12V mutations. It effectively inhibits RAS mutant cell lines GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 is applicable for cancer research.</p>Formula:C30H37FN10OSColor and Shape:SolidMolecular weight:604.745KRAS G12C inhibitor 44
<p>KRAS G12C inhibitor 44: potent, oral, anti-cancer; halts cell growth in MIA PaCA-2, H358; effective in vivo. IC50: MIA-0.016μM, H358-0.028μM.</p>Formula:C31H36ClFN6O2Color and Shape:SolidMolecular weight:579.11Rho GTPase inhibitor 1
CAS:<p>Rho GTPase inhibitor 1 (compound 7) is a potent inhibitor of Rho GTPase. It exhibits high affinity for Cdc42, Rac1, and RhoA, with dissociation constants (KDs) of 151 μM, 352 μM, and 232 μM, respectively. Additionally, Rho GTPase inhibitor 1 reduces cell migration in glioblastoma cell lines.</p>Formula:C18H16N2OColor and Shape:SolidMolecular weight:276.33MEK4 inhibitor-2
CAS:<p>MEK4 Inhibitor-2, a novel MEK4 inhibitor, demonstrates efficacy against pancreatic adenocarcinoma, exhibiting an IC50 value of 83 nM.</p>Formula:C20H15FN4O3SColor and Shape:SolidMolecular weight:410.42EBI-907
CAS:<p>EBI-907 is a potent, oral B-RafV600E inhibitor with an IC50 of 4.9 nM, over 10x stronger than Vemurafenib, and effective against key cancer kinases.</p>Formula:C23H21ClF2N4O3SColor and Shape:SolidMolecular weight:506.95L 739749
CAS:<p>L 739749 is a CAAX peptidomimetic. It is also an inhibitor of farnesyl-protein transferase.</p>Formula:C24H41N3O6S2Purity:98%Color and Shape:SolidMolecular weight:531.73LSN3074753
CAS:<p>LSN3074753, a derivative of LY3009120, acts as a pan-RAF and Raf dimer inhibitor. This compound exhibits inhibitory activity against tumor cells driven by either BRAF monomers or RAF dimers, particularly in the activation of the MAPK pathway, including colorectal cancers with BRAF or KRAS mutations. When combined with Cetuximab, LSN3074753 demonstrates additive and synergistic effects in colorectal cancer PDX models, especially in those harboring KRAS or BRAF mutations.</p>Formula:C24H30FN5O2Color and Shape:SolidMolecular weight:439.53Fulzerasib
CAS:<p>Fulzerasib is an orally active KRAS G12C inhibitor that covalently binds to cysteine residue on the protein, thereby inhibiting the growth of KRAS G12C mutant</p>Formula:C32H30ClFN6O4Purity:98.04%Color and Shape:SolidMolecular weight:617.07SOS1-IN-6
CAS:<p>SOS1-IN-6 (compound 33-P1) is a potent inhibitor of SOS1, acting on SOS1-G12D (IC50: 14.9 nM) and SOS1-G12V (IC50: 73.3 nM).</p>Formula:C26H28F3N3O2Color and Shape:SolidMolecular weight:471.51HPK1-IN-21
<p>HPK1-IN-21 is a potent, orally active HPK1 kinase inhibitor with a Ki value of 0.8 nM.</p>Formula:C22H25ClFN5O2Color and Shape:SolidMolecular weight:445.92Cot inhibitor-3
CAS:<p>Cot inhibitor-3 (Compound 33) is an effective and selective cancerosaka thyroid (COT) kinase inhibitor with an IC50 of 4 nM. It can be used to prevent limpness caused by inflammation.</p>Formula:C30H28N8OColor and Shape:SolidMolecular weight:516.60MEK1/2-IN-2
<p>MEK1/2-IN-2 is a potent, ATP-competitive MEK1/2 inhibitor that exhibits equal inhibitory effects on wild-type MEK1/2 and a group of MEK1/2 mutant cells.</p>Formula:C28H22ClFN6OColor and Shape:SolidMolecular weight:512.97BMS-214662
CAS:<p>BMS-214662 is a selective farnesyl transferase inhibitor with anti-tumor activity, used in research on pancreatic cancer, head and neck cancer, and lung cancer.</p>Formula:C25H23N5O2S2Purity:99.58% - 99.58%Color and Shape:SolidMolecular weight:489.61HPK1-IN-16
CAS:<p>HPK1-IN-16, a potent HPK1 inhibitor, useful for cancer research and treatment.</p>Formula:C28H27FN4OColor and Shape:SolidMolecular weight:454.54HPK1-IN-31
<p>HPK1-IN-31 inhibitor with an IC 50 value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunotherapy .</p>Formula:C30H33N7O3Color and Shape:SolidMolecular weight:539.63AMG-548 dihydrochloride
<p>AMG-548 dihydrochloride, an oral p38α inhibitor (Ki: 0.5 nM), selectively targets p38β, γ, δ, inhibits TNFα (IC50: 3 nM), and suppresses Wnt signaling.</p>Formula:C29H29Cl2N5OColor and Shape:SolidMolecular weight:534.48K-Ras-IN-4
CAS:<p>K-Ras-IN-4 (compound CP163) is an inhibitor of K-Ras.</p>Formula:C31H28F4N6O3SColor and Shape:SolidMolecular weight:640.65ERK2 IN-1
CAS:<p>ERK2 IN-1 is a selective ERK2 inhibitor with an IC50 of 7 nM.</p>Formula:C36H34FN7O2SPurity:98%Color and Shape:SolidMolecular weight:647.76HPK1-IN-30
CAS:<p>HPK1-IN-30 is a potent inhibitor of HPK1. HPK1-IN-30 has potential for cancer disease research.</p>Formula:C25H23FN6Color and Shape:SolidMolecular weight:426.49ATX inhibitor 26
CAS:<p>ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. It effectively inhibits cell migration and collagen gel contraction. Additionally, ATX inhibitor 26 demonstrates significant antifibrotic activity, reducing collagen deposition in a Bleomycin (BLM)-induced pulmonary fibrosis model.</p>Formula:C18H19Cl2N7O3Color and Shape:SolidMolecular weight:452.30VVD-699
CAS:<p>VVD-699 is a covalent inhibitor of RAS-PI3K. It forms a covalent bond with cysteine at position 242 within the RAS-binding domain of PI3Kp110α, thereby obstructing the ability of RAS to activate PI3K. VVD-699 is capable of inhibiting the growth of tumors with RAS mutations and HER2 overexpression. It is applicable in research related to RAS mutation-associated cancers, such as those involving H358 lung cancer cells, A549 cells, and FaDu cells.</p>Formula:C25H30ClFN2O6S2Color and Shape:SolidMolecular weight:573.097SHR2415
<p>SHR2415: Potent, selective ERK1/2 inhibitor, oral; ERK1 IC50: 2.8 nM, ERK2 IC50: 5.9 nM; effective in Colo205 (IC50: 44.6 nM), for cancer research.</p>Formula:C23H22ClN7O2Color and Shape:SolidMolecular weight:463.92HPK1-IN-55
CAS:<p>HPK1-IN-55 (compound 19) is a selective and orally active inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an IC50 of less than 0.51 nM. It exhibits exceptional kinase selectivity, being over 637 times more selective for HPK1 compared to GCK kinase and over 1022 times compared to LCK. HPK1-IN-55 possesses anti-cancer properties.</p>Formula:C30H34N8O3Color and Shape:SolidMolecular weight:554.643KRAS G12D inhibitor 3
CAS:<p>KRAS G12D Inhibitor 3, a compound targeting the KRAS G12D mutation, demonstrates potent antitumor efficacy with an inhibitory concentration (IC50) of less than</p>Formula:C34H31ClF3N5O2Color and Shape:SolidMolecular weight:634.09Sosimerasib
CAS:<p>Sosimerasib is an inhibitor of the kirsten rat sarcoma viral oncogene homolog (KRAS) and exhibits antitumor activity.</p>Formula:C36H39ClFN7O4Color and Shape:SolidMolecular weight:688.191MRTX849 ethoxypropanoic acid
CAS:<p>MRTX849 is a KRAS G12C ligand and PROTAC linker for creating potent LC-2, degrading KRAS G12C with DC50 of 0.25-0.76 μM.</p>Formula:C37H43ClFN7O5Color and Shape:SolidMolecular weight:720.24KRAS G12D inhibitor 12
<p>KRAS G12D inhibitor 12 targets Ras protein for cancer research. (Patent WO2021108683A1, Compound 134)</p>Formula:C23H21ClFN5O3Color and Shape:SolidMolecular weight:469.9ERK-IN-2
CAS:<p>ERK-IN-2, an ERK2 inhibitor, exhibits an IC50 value of 1.8 nM. At doses greater than 10 μM, it may induce off-target toxicity and/or activity [1].</p>Formula:C16H18ClN5O2Purity:98%Color and Shape:SolidMolecular weight:347.80SML-10-70-1
CAS:<p>SML-10-70-1 is a Novel Active Site Inhibitor of Oncogenic K-Ras G12C.</p>Formula:C25H42ClN7O13P2Color and Shape:SolidMolecular weight:746.04Dorrigocin A
CAS:<p>Dorrigocin A, an analog of Migrastatin, inhibits the carboxymethyltransferase involved in Ras processing, reversing the morphology of Ras-transformed NIH/3T3 cells. Dorrigocin A holds potential for research as an anticancer and anti-arthritis agent.</p>Formula:C27H41NO8Color and Shape:SolidMolecular weight:507.616SOF-436
CAS:<p>SOF-436 is a KRAS inhibitor that can suppress SOS1-mediated KRAS nucleotide exchange (IC50 = 60 μM) and inhibit the interaction between KRAS and the effector protein RAF. SOF-436 is applicable to cancer research.</p>Formula:C15H13F2NO4S2Color and Shape:SolidMolecular weight:373.395JAK3-IN-13
<p>JAK3-IN-13: Oral JAK3 inhibitor, selective & potent. Acts on NK1, JNK2, JNK3, Tyk2. Anti-tumor. IC50: JNK3, 8 nM; Tyk2, 365 nM; JNK2, 2039 nM; NK1, 4728 nM.</p>Formula:C25H33ClN6O5Color and Shape:SolidMolecular weight:533.02
